2.2.0.25falsefalse0201 - Disclosure - Summary of significant accounting policiestruefalsefalse1falsefalseUSDfalsefalse1/1/2011 - 3/31/2011
USD ($)
USD ($) / shares
$Jan-01-2011_Mar-31-2011http://www.sec.gov/CIK0000820237duration2011-01-01T00:00:002011-03-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0gpro_SummaryOfSignificantAccountingPoliciesAbstractgprofalsenadurationSummary Of Significant Accounting Policies.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringSummary Of Significant Accounting Policies.falsefalse3false0us-gaap_SignificantAccountingPoliciesTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 1 - us-gaap:SignificantAccountingPoliciesTextBlock-->
<!-- xbrl,ns -->
<!-- xbrl,nx -->
<div style="font-family: 'Times New Roman',Times,serif">
<div align="left">
</div>
<div align="left" style="font-size: 10pt; margin-top: 0pt"><b></b>
</div>
<div align="left" style="font-size: 10pt; margin-top: 12pt"><b>Note 1 — Summary of Significant Accounting Policies</b>
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt"><b><i>Basis of Presentation</i></b>
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The accompanying interim consolidated financial statements of Gen-Probe Incorporated
(“Gen-Probe” or the “Company”) at March 31, 2011, and for the three month periods ended March 31,
2011 and 2010, are unaudited and have been prepared in accordance with United States generally
accepted accounting principles (“U.S. GAAP”) for interim financial information. Accordingly, they
do not include all of the information and footnotes required by U.S. GAAP for complete financial
statements. In management’s opinion, the unaudited consolidated financial statements include all
adjustments, consisting only of normal recurring accruals, necessary to state fairly the financial
information therein, in accordance with U.S. GAAP. Interim results are not necessarily indicative
of the results that may be reported for any other interim period or for the year ending December
31, 2011.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     These unaudited interim consolidated financial statements and related footnotes should be read
in conjunction with the audited consolidated financial statements and related footnotes contained
in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     In accordance with the Financial Accounting Standards Board
(“FASB”) Accounting Standards Codification (“ASC”) Topic 855, Subsequent Events, the Company evaluated subsequent events after
the balance sheet date of March 31, 2011 and through the date and time its consolidated financial
statements were issued on May 4, 2011.
</div>
<div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Principles of Consolidation</i></b>
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     These unaudited consolidated financial statements include the accounts of Gen-Probe as well as
its wholly owned subsidiaries. All material intercompany transactions and balances have been
eliminated in consolidation. The Company does not consolidate any interests in variable interest
entities.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     In December 2010, the Company acquired Genetic Testing Institute, Inc. (“GTI Diagnostics”), a
privately held Wisconsin corporation now known as Gen-Probe GTI Diagnostics, Inc. GTI Diagnostics
has broadened and strengthened the Company’s transplant diagnostics business, and has also provided
the Company with access to new products in the specialty coagulation and transfusion-related blood
bank markets. GTI Diagnostics’ results of operations have been included in the Company’s
consolidated financial statements beginning in December 2010.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     In October 2009, the Company acquired Prodesse, Inc. (“Prodesse”), a privately held Wisconsin
corporation, now known as Gen-Probe Prodesse, Inc. Prodesse develops molecular diagnostic products
for a variety of infectious disease applications. Prodesse’s results of operations have been
included in the Company’s consolidated financial statements beginning in October 2009.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     In April 2009, the Company acquired Tepnel Life Sciences plc (“Tepnel”), a United Kingdom
(“UK”) based international life sciences products and services company, now known as Gen-Probe Life
Sciences Ltd. Tepnel’s transplant diagnostics and genetic testing results of operations have been
included in the Company’s consolidated financial statements beginning in April 2009.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company translates the financial statements of its non-U.S. operations using the
end-of-period exchange rates for assets and liabilities and the average exchange rates for each
reporting period for results of operations. Net gains and losses resulting from the translation of
foreign financial statements and the effect of exchange rates on intercompany receivables and
payables of a long-term investment nature are recorded as a separate component of stockholders’
equity under the caption “Accumulated other comprehensive (loss) income.” These adjustments will
affect net income upon the sale or liquidation of the underlying investment.
</div>
<!-- Folio -->
<!-- /Folio -->
</div>
<!-- PAGEBREAK -->
<div style="font-family: 'Times New Roman',Times,serif">
<div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Use of Estimates</i></b>
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The preparation of financial statements in conformity with U.S. GAAP requires management to
make certain estimates and assumptions that affect the amounts reported in the consolidated
financial statements. These estimates include assessing the collectability of accounts receivable,
recognition of revenues, and the valuation of the following: stock-based compensation; marketable
securities; equity investments in publicly and privately held companies; income tax; liabilities
associated with employee benefit costs; inventories; and goodwill and long-lived assets, including
patent costs, capitalized software, purchased intangibles and licenses and manufacturing access
fees. Actual results could differ from those estimates.
</div>
<div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Segment Information</i></b>
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company currently operates in one business segment, the development, manufacturing,
marketing, sales and support of molecular diagnostic products primarily to diagnose human diseases,
screen donated human blood and ensure transplant compatibility. Although the Company’s products
comprise distinct product lines to serve different end markets within molecular diagnostics, the
Company does not operate its business in operating segments. The Company is managed by a single
functionally based management team that manages all aspects of the Company’s business and reports
directly to the Chief Executive Officer. For all periods presented, the Company operated in a
single business segment. Revenue by product line is presented in Note 11.
</div>
<div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Revenue Recognition</i></b>
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company records shipments of its clinical diagnostic products as product sales when the
product is shipped, title and risk of loss have passed to the customer and when collection of the resulting
receivable is reasonably assured.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company manufactures blood screening products according to demand schedules provided by
its collaboration partner, Novartis Vaccines and Diagnostics, Inc. (“Novartis”). Upon shipment to
Novartis, the Company recognizes blood screening product sales at an agreed upon transfer price and
records the related cost of products sold. Based on the terms of the Company’s collaboration
agreement with Novartis, the Company’s ultimate share of the net revenue from sales to the end user
is not known until reported to the Company by Novartis. The Company then adjusts blood screening
product sales upon receipt of customer revenue reports and a net payment from Novartis of amounts
reflecting the Company’s ultimate share of net sales by Novartis for these products, less the
transfer price revenues previously recognized.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     In most cases, the Company provides its instrumentation to its clinical diagnostics customers
without requiring them to purchase the equipment or enter into an equipment lease. Instead, the
Company recovers the cost of providing the instrumentation in the amount it charges for its
diagnostic assays. The depreciation costs associated with an instrument are charged to cost of
product sales on a straight-line basis over the estimated life of the instrument. The costs to
maintain these instruments in the field are charged to cost of product sales as incurred.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company sells its instruments to Novartis for use in blood screening and records these
instrument sales upon delivery since Novartis is responsible for the placement, maintenance and
repair of the units with its customers. The Company also sells instruments to its clinical
diagnostics customers and records sales of these instruments upon delivery and receipt of customer
acceptance. Prior to delivery, each instrument is tested to meet Gen-Probe’s and United States Food
and Drug Administration (“FDA”) specifications, and is shipped fully assembled. Customer acceptance
of the Company’s clinical diagnostic instrument systems requires installation and training by the
Company’s technical service personnel. Installation is a standard process consisting principally of
uncrating, calibrating and testing the instrumentation.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company records revenue on its research products and services in the period during which
the related costs are incurred, or services are provided. This revenue consists of outsourcing
services for the pharmaceutical, biotechnology and healthcare industries, including nucleic acid
purification and analysis services, as well as the sale of monoclonal antibodies.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company analyzes each element of its collaborative arrangements to determine the
appropriate revenue recognition. The Company recognizes revenue on up-front payments over the
period of significant involvement
under the related agreements unless the fee is in exchange for products delivered or services
rendered that represent the culmination of a separate earnings process and no further performance
obligation exists under the contract.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     Revenue arrangements with multiple deliverables are evaluated for proper accounting treatment.
In these arrangements, the Company records revenue as separate units of accounting if the
delivered items have value to the customer on a stand-alone basis, and if the arrangement includes
a general right of return relative to the delivered items, and delivery or performance of the
undelivered items is considered probable and substantially within the Company’s control. For
transactions entered into prior to 2011, consideration was generally allocated to each unit of
accounting based on its relative fair value when objective and reliable evidence of fair value
existed for all units of accounting in an arrangement. The fair value of an item was generally the
price charged for the product, if the item was sold on a stand-alone basis. When the Company was
unable to establish fair value for delivered items or when fair value of undelivered items had not
been established, revenue was deferred until all elements were delivered and services had been
performed or until fair value could be objectively determined for any undelivered elements.
Beginning in 2011, arrangement consideration is allocated at the inception of the arrangement to
all deliverables using the relative selling price method that is based on a three-tier hierarchy.
The relative selling price method requires that the estimated selling price for each deliverable be
based on vendor-specific objective evidence (“VSOE”) of fair value, which represents the price
charged for each deliverable when it is sold separately or for a deliverable not yet being sold
separately, the price established by management having the relevant authority. When VSOE of fair
value is not available, third-party evidence (“TPE”) of fair value is acceptable, or a best
estimate of selling price if VSOE and TPE are not available. A best estimate of selling price
should be consistent with the objective of determining the price at which the Company would
transact if the deliverable were sold regularly on a stand-alone basis and should also take into
account market conditions and company specific factors.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company recognizes collaborative research revenue over the term of various collaboration
agreements, as negotiated monthly contracted amounts are earned or reimbursable costs are incurred
related to those agreements. Negotiated monthly contracted amounts are earned in relative
proportion to the performance required under the applicable contracts. Non-refundable license fees
are recognized over the related performance period or at the time that the Company has satisfied
all performance obligations. Milestone consideration that is contingent upon achievement of a
milestone in its entirety is recorded as revenue in the period in which the milestone is achieved
only if the milestone meets all criteria to be considered substantive. These criteria include (i)
the consideration being earned should be commensurate with either the Company’s performance to
achieve the milestone or the enhancement of the value of the item delivered as a result of a
specific outcome resulting from the Company’s performance to achieve the milestone, (ii) the
consideration being earned should relate solely to past performance, (iii) the consideration being
earned should be reasonable relative to all deliverables and payment terms in the arrangement, and
(iv) the milestone should be considered in its entirety and cannot be bifurcated into substantive
and non-substantive components. Any amounts received prior to satisfying the Company’s revenue
recognition criteria are recorded as deferred revenue on its consolidated balance sheets.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     Royalty and license revenue is recognized related to the sale or use of the Company’s products
or technologies under license agreements with third parties. For those arrangements where royalties
are reasonably estimable, the Company recognizes revenue based on estimates of royalties earned
during the applicable period and adjusts for differences between the estimated and actual royalties
in the following period. Historically, these adjustments have not been material. For those
arrangements where royalties are not reasonably estimable, the Company recognizes revenue upon
receipt of royalty statements from the applicable licensee.
</div>
<div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Stock-based Compensation</i></b>
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     Stock-based compensation expense is recognized for restricted stock, deferred issuance
restricted stock, performance stock awards, which include awards subject to performance conditions
and/or market conditions, stock options, and shares purchasable under the Company’s Employee Stock
Purchase Plan (“ESPP”). Stock-based compensation expense for restricted stock, deferred issuance
restricted stock, and performance condition stock awards is measured based on the closing fair
market value of the Company’s common stock on the date of grant. Stock-based compensation expense
for market condition stock awards is measured based on the fair value of the award on the date of
grant using a Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple
point variables that determine the probability of satisfying the market condition stipulated in the
grant and calculates the fair value of the award.
</div>
<!-- Folio -->
<!-- /Folio -->
</div>
<!-- PAGEBREAK -->
<div style="font-family: 'Times New Roman',Times,serif">
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company uses the Black-Scholes-Merton option pricing model to value stock options granted.
The determination of the fair value of share-based payment awards on the date of grant using the
Black-Scholes-Merton model is affected by the Company’s stock price and the implied volatility on
its traded options, as well as the input of other subjective assumptions. These assumptions
include, but are not limited to, the expected term of stock options and the Company’s expected
stock price volatility over the term of the awards.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company used the following weighted average assumptions to estimate the fair value of
stock options and performance stock awards granted under the Company’s equity incentive plans and
the shares purchasable under the Company’s ESPP, as well as the resulting average fair values for
the three month periods ended March 31, 2011 and 2010:
</div>
<div align="center">
<table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<tr valign="bottom">
<td width="76%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="6"><b>Three Months Ended</b></td>
<td> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>March 31,</b></td>
<td> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
<td> </td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px"><b><i>Stock option plans</i></b>
</div></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:30px; text-indent:-15px">Risk-free interest rate
</div></td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">1.7</td>
<td nowrap="nowrap">%</td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">2.1</td>
<td nowrap="nowrap">%</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:30px; text-indent:-15px">Volatility
</div></td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">31</td>
<td nowrap="nowrap">%</td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">32</td>
<td nowrap="nowrap">%</td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:30px; text-indent:-15px">Dividend yield
</div></td>
<td> </td>
<td> </td>
<td align="right">—</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">—</td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:30px; text-indent:-15px">Expected term (years)
</div></td>
<td> </td>
<td> </td>
<td align="right">4.3</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">4.4</td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:30px; text-indent:-15px">Resulting average fair value
</div></td>
<td> </td>
<td align="left">$</td>
<td align="right">17.46</td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">12.71</td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px"><b><i>Performance stock awards </i></b><sup style="font-size: 85%; vertical-align: text-top"><b><i>(1)</i></b></sup>
</div></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:30px; text-indent:-15px">Risk-free interest rate
</div></td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">1.3</td>
<td nowrap="nowrap">%</td>
<td> </td>
<td> </td>
<td align="right">—</td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:30px; text-indent:-15px">Volatility
</div></td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">33</td>
<td nowrap="nowrap">%</td>
<td> </td>
<td> </td>
<td align="right">—</td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:30px; text-indent:-15px">Dividend yield
</div></td>
<td> </td>
<td> </td>
<td align="right">—</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">—</td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:30px; text-indent:-15px">Expected term (years)
</div></td>
<td> </td>
<td> </td>
<td align="right">2.9</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">—</td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:30px; text-indent:-15px">Resulting average fair value
</div></td>
<td> </td>
<td align="left">$</td>
<td align="right">82.58</td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">—</td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px"><b><i>ESPP</i></b>
</div></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:30px; text-indent:-15px">Risk-free interest rate
</div></td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">0.2</td>
<td nowrap="nowrap">%</td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">0.2</td>
<td nowrap="nowrap">%</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:30px; text-indent:-15px">Volatility
</div></td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">22</td>
<td nowrap="nowrap">%</td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">26</td>
<td nowrap="nowrap">%</td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:30px; text-indent:-15px">Dividend yield
</div></td>
<td> </td>
<td> </td>
<td align="right">—</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">—</td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:30px; text-indent:-15px">Expected term (years)
</div></td>
<td> </td>
<td> </td>
<td align="right">0.5</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">0.5</td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:30px; text-indent:-15px">Resulting average fair value
</div></td>
<td> </td>
<td align="left">$</td>
<td align="right">12.27</td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">9.65</td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
</div>
<div align="left">
<div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"> 
</div>
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
<tr>
<td width="3%"></td>
<td width="1%"></td>
<td width="96%"></td>
</tr>
<tr valign="top">
<td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><b><i>(1)</i></b></sup></td>
<td> </td>
<td>These assumptions apply to the Company’s market condition stock awards granted in
2011. Performance condition stock awards granted in 2010 were valued at $42.66 based on the closing
fair market value of the Company’s common stock on the date of grant.</td>
</tr>
</table>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company’s unrecognized stock-based compensation expense as of March 31, 2011, before
income taxes and adjusted for estimated forfeitures, related to outstanding unvested share-based
payment awards was approximately as follows (in thousands, except number of years):
</div>
<div align="center">
<table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<tr valign="bottom">
<td width="76%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Weighted Average</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Unrecognized</b></td>
<td> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Remaining</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Expense as of</b></td>
<td> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Expense Life</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>March 31, </b></td>
<td> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"><b>Awards</b></td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>(Years)</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
<td> </td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px">Options
</div></td>
<td> </td>
<td> </td>
<td align="right">2.9</td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">35,608</td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:15px; text-indent:-15px">Employee stock purchase plan
</div></td>
<td> </td>
<td> </td>
<td align="right">0.2</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">80</td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px">Performance stock awards
</div></td>
<td> </td>
<td> </td>
<td align="right">2.8</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">7,694</td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:15px; text-indent:-15px">Restricted stock
</div></td>
<td> </td>
<td> </td>
<td align="right">1.5</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">3,366</td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px">Deferred issuance restricted stock
</div></td>
<td> </td>
<td> </td>
<td align="right">1.7</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">993</td>
<td> </td>
</tr>
<tr style="font-size: 1px">
<td>
<div style="margin-left:15px; text-indent:-15px"> 
</div></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:15px; text-indent:-15px">Total
</div></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">47,741</td>
<td> </td>
</tr>
<tr style="font-size: 1px">
<td>
<div style="margin-left:15px; text-indent:-15px"> 
</div></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
</div>
<!-- Folio -->
<!-- /Folio -->
</div>
<!-- PAGEBREAK -->
<div style="font-family: 'Times New Roman',Times,serif">
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The following table summarizes the stock-based compensation expense that the Company recorded
in its consolidated statements of income for the three month periods ended March 31, 2011 and 2010
(in thousands):
</div>
<div align="center">
<table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<tr valign="bottom">
<td width="76%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="6"><b>Three Months Ended</b></td>
<td> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>March 31,</b></td>
<td> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
<td> </td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px">Cost of product sales
</div></td>
<td> </td>
<td align="left">$</td>
<td align="right">788</td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">864</td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:15px; text-indent:-15px">Research and development
</div></td>
<td> </td>
<td> </td>
<td align="right">1,792</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">1,679</td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px">Marketing and sales
</div></td>
<td> </td>
<td> </td>
<td align="right">612</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">802</td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:15px; text-indent:-15px">General and administrative
</div></td>
<td> </td>
<td> </td>
<td align="right">2,844</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">2,557</td>
<td> </td>
</tr>
<tr style="font-size: 1px">
<td>
<div style="margin-left:15px; text-indent:-15px"> 
</div></td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px">Total
</div></td>
<td> </td>
<td align="left">$</td>
<td align="right">6,036</td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">5,902</td>
<td> </td>
</tr>
<tr style="font-size: 1px">
<td>
<div style="margin-left:15px; text-indent:-15px"> 
</div></td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
</div>
<div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Net Income Per Share</i></b>
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     Diluted net income per share is reported based on
the more dilutive of the treasury stock or the two-class method. Under the two-class method,
net income is allocated to common stock and participating securities. The Company’s restricted
stock, deferred issuance restricted stock and performance stock awards meet the definition of
participating securities. Basic net income per share under the two-class method is computed by
dividing net income adjusted for earnings allocated to unvested stockholders for the period by the
weighted average number of common shares outstanding during the period. Diluted net income per
share under the two-class method is computed by dividing net income adjusted for earnings allocated
to unvested stockholders for the period by the weighted average number of common and common
equivalent shares outstanding during the period. The Company excludes stock options
from the calculation of diluted net income per share when the combined exercise price, average
unamortized fair values and assumed tax benefits upon exercise are greater than the average market
price for the Company’s common stock because their effect is anti-dilutive. Potentially dilutive
securities totaling approximately 688,000 and 4,179,000 for the three month periods ended March 31,
2011 and 2010, respectively, were excluded from the calculations of diluted earnings per share (“EPS”)
below because of their anti-dilutive effect.
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     The following table sets forth the computation of basic and diluted EPS for the three month
periods ended March 31, 2011 and 2010 (in thousands, except per share amounts):
</div>
<div align="center">
<table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<tr valign="bottom">
<td width="40%"> </td>
<td width="3%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="3%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="3%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="3%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="3%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
<td width="3%"> </td>
<td width="1%"> </td>
<td width="5%"> </td>
<td width="1%"> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="22" style="border-bottom: 1px solid #000000"><b>Three Months Ended March 31,</b></td>
<td> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>2011</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>2010</b></td>
<td> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"> </td>
<td> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"> </td>
<td> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Shares</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Per Share</b></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Shares</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2"><b>Per Share</b></td>
<td> </td>
</tr>
<tr style="font-size: 8pt" valign="bottom">
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Income</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Outstanding</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Amount</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Income</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Outstanding</b></td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Amount</b></td>
<td> </td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px">Net income
</div></td>
<td> </td>
<td align="left">$</td>
<td align="right">23,277</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">24,193</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr valign="bottom"><!-- Blank Space -->
<td>
<div style="margin-left:15px; text-indent:-15px"> 
</div></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:15px; text-indent:-15px">Less: Earnings allocated to unvested stockholders
</div></td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">(35</td>
<td nowrap="nowrap">)</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">(101</td>
<td nowrap="nowrap">)</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr style="font-size: 1px">
<td>
<div style="margin-left:15px; text-indent:-15px"> 
</div></td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px"><b>Basic EPS</b>
</div></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:15px; text-indent:-15px">Distributable income available to common
stockholders
</div></td>
<td> </td>
<td> </td>
<td align="right">23,242</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">47,861</td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">0.49</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">24,092</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">49,233</td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">0.49</td>
<td> </td>
</tr>
<tr style="font-size: 1px">
<td>
<div style="margin-left:15px; text-indent:-15px"> 
</div></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px">Effect of dilutive securities:
</div></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:15px; text-indent:-15px">Add back: Undistributed earnings allocated to
unvested stockholders
</div></td>
<td> </td>
<td> </td>
<td align="right">35</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">89</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">101</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px">Dilutive stock options
</div></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">1,054</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">506</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr valign="bottom">
<td>
<div style="margin-left:15px; text-indent:-15px">Less: Undistributed earnings reallocated to
unvested stockholders
</div></td>
<td> </td>
<td> </td>
<td align="right">—</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" align="left"> </td>
<td align="right">(100</td>
<td nowrap="nowrap">)</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr style="font-size: 1px">
<td>
<div style="margin-left:15px; text-indent:-15px"> 
</div></td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td>
<div style="margin-left:15px; text-indent:-15px"><b>Diluted EPS — Common stock</b>
</div></td>
<td> </td>
<td align="left">$</td>
<td align="right">23,277</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">49,004</td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">0.48</td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">24,093</td>
<td> </td>
<td> </td>
<td> </td>
<td align="right">49,739</td>
<td> </td>
<td> </td>
<td align="left">$</td>
<td align="right">0.48</td>
<td> </td>
</tr>
<tr style="font-size: 1px">
<td>
<div style="margin-left:15px; text-indent:-15px"> 
</div></td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td>
<td> </td>
<td> </td>
<td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
</div>
<!-- Folio -->
<!-- /Folio -->
</div>
<!-- PAGEBREAK -->
<div style="font-family: 'Times New Roman',Times,serif">
<div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Adoption of Recent Accounting Pronouncements</i></b>
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><i>Accounting Standards Update 2010-06</i>
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     In January 2010, the FASB amended ASC Topic 820, Fair Value Measurements and Disclosures, to
require reporting entities to make new disclosures about recurring and non-recurring fair value
measurements, including significant transfers into and out of Level 1 and Level 2 fair value
measurements and information about purchases, sales, issuances, and settlements on a gross basis in
the reconciliation of Level 3 fair value measurements. Except for the detailed Level 3 roll forward
disclosures, the guidance was effective January 1, 2010. The new disclosures about purchases,
sales, issuances, and settlements in the roll forward activity for Level 3 fair value measurements
were effective for the Company as of January 1, 2011. Upon adoption, the guidance did not have a
material impact on the Company’s consolidated financial statements and is not expected to have a
material impact on its future operating results.
</div>
<div align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 2%"><i>Accounting Standards Update 2010-17</i>
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     In March 2010, the FASB ratified the final consensus that offers an alternative method of
revenue recognition for milestone payments. The guidance states that an entity can make an
accounting policy election to recognize a payment that is contingent upon the achievement of a
substantive milestone in its entirety in the period in which the milestone is achieved. The
guidance will be effective for fiscal years, and interim periods within those years, beginning on
or after June 15, 2010 with early adoption permitted, provided that the revised guidance is applied
retrospectively to the beginning of the year of adoption. The Company elected to adopt this
guidance prospectively, effective for the Company’s fiscal year beginning January 1, 2011. Upon
adoption, the guidance did not have a material impact on the Company’s consolidated financial
statements and is not expected to have a material impact on its future operating results.
</div>
<div align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 2%"><i>Accounting Standards Update 2009-13</i>
</div>
<div align="left" style="font-size: 10pt; margin-top: 6pt">     In September 2009, the FASB revised the authoritative guidance for revenue arrangements with
multiple deliverables. The guidance addresses how to determine whether an arrangement involving
multiple deliverables contains more than one unit of accounting and how the arrangement
consideration should be allocated among the separate units of accounting. The guidance may be
applied retrospectively or prospectively for new or materially modified arrangements. The Company
elected to adopt this guidance prospectively, effective for the Company’s fiscal year beginning
January 1, 2011. Upon adoption, the guidance did not have a material impact on the Company’s
consolidated financial statements and is not expected to have a material impact on its future
operating results.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThis element may be used to describe all significant accounting policies of the reporting entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 22
-Paragraph 8
falsefalse12Summary of significant accounting policiesUnKnownUnKnownUnKnownUnKnownfalsetrue